PRESS RELEASE                                         Share Buyback Transaction Details May 29 – June 4, 2025 Alphen aan den Rijn – June 5, 2025 – Wolters Kluwer (Euronext: WKL), a global leader in professional information solutions, software and services, today reports that it has repurchased 225,452 of its own ordinary shares in the period from May 29, 2025, up to and including June 4, 2025, for €35.2 million and at an average share price of €155.93. These repurchases are part of the share buyback program announced on February 26, 2025, under which we intend to repurchase shares for up to € 1 billion during 2025. The cumulative amounts repurchased in the year to date under this program are as follows: Share Buyback 2025Period Cumulative shares repurchased in period Total consideration(€ million) Average share price(€)2025...

June 5, 2025 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), today announced that the exchange ratio for the dividend for the year 2024 is 1 new common share for every 23.6353 existing common shares. This ratio was based on the volume weighted average price on Euronext Amsterdam of May 30, June 2, and 3, 2025, of EUR 20.0600 and was calculated in a manner that the gross dividend in shares will be approximately equal to EUR 0.85. As a result, Philips will issue a total number of 22,980,748 new common shares. Shareholders have been given the opportunity to make their choice between a dividend in shares or (subject to certain conditions) in cash. The aggregate cash election result was 41.4%, which is below the 50% maximum as adopted in the General Meeting of Shareholders and therefore shareholders will receive the dividend...

Sanofi Launches 2025 Global Employee Stock Purchase Plan Paris, June 5, 2025. Sanofi’s global employee shareholder plan, Action 2025, opens on June 10, 2025, to around 70,000 employees in 55 countries. Now in its 11th year, the program demonstrates the ongoing commitment of Sanofi and its Board of Directors to involve employees in the company’s growth and results. In 2024 alone, more than 32,000 Sanofi employees – 40% of the total workforce, chose to invest in the company through the program. Today, nearly 90,000 current or former Sanofi employees are shareholders, and hold approximately 2.55%1 of its capital. Paul HudsonChief Executive Officer of Sanofi“The Board of Directors and I are particularly proud to see the growing participation of our employees in our global employee shareholder plan, a commitment that has endured...

ZUG, Switzerland, June 05, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), today announced the results from its 2025 Annual General Meeting held on June 4, 2025 at Ochsen-Zug, Kolinplatz 11, CH-6300 Zug, Switzerland, at 3:00 p.m. CEST / 9:00 a.m. EDT. The Company’s shareholders approved all agenda items. The shareholders approved the 2024 Annual Report including the 2024 Annual (Statutory) Financial Statements and the 2024 Consolidated Financial Statements. The shareholders acknowledged that on a standalone statutory financial statement basis, the Company incurred a loss of CHF 5,179,000 with respect to the financial year ended December 31, 2024, and resolved that the accumulated balance sheet loss of CHF 46,577,000 shall be carried forward to the new accounts. The members of the...

Transaction finalized with issuance of 125,000 preferred MEME Coin shares; token transfer confirmed on BSCScan Mesquite, June 05, 2025 (GLOBE NEWSWIRE) — June 5, 2025 – Mesquite, NV — Dogecoin Cash Inc. (OTC: CBDS) announced today that its wholly owned subsidiary, MEME Coins Inc., has successfully closed the acquisition of 1 billion DogeCoin Cash (CRYPTO:DOG) from Tipestry Inc., a social blockchain company. The transaction, which was completed yesterday, involved the issuance of 125,000 preferred shares of MEME Coins Inc., under a revised agreement from the originally proposed 500,000 shares. “This marks a major milestone in MEME Coins Inc.’s strategy to secure high-value digital assets as we build out our blockchain-based ecosystem,” said a CBDS company representative. “DOG tokens have the potential to be a strong utility and...

Dassault Aviation partners with Tata Advanced Systems to manufacture Rafale fighter aircraft fuselage for India and other global marketsFirst-ever Rafale fuselage production in India Dedicated manufacturing facility to be set up in Hyderabad(Saint-Cloud, Mumbai, June 5, 2025) – Dassault Aviation and Tata Advanced Systems Limited have signed four Production Transfer Agreements to manufacture the Rafale fighter aircraft fuselage in India, marking a significant step forward in strengthening the country’s aerospace manufacturing capabilities and supporting global supply chains. This facility represents a significant investment in India’s aerospace infrastructure and will serve as a critical hub for high-precision manufacturing. Under the scope of the partnership, Tata Advanced Systems will set up a cutting-edge production facility...

UAB “Kvartalas”, legal entity code 305475438, with its registered address at Jogailos St. 4, Vilnius, Republic of Lithuania (the Issuer), announces that, due to sufficient investor demand, the Issuer has decided to end the subscription process for the offering of the 3rd tranche of bonds (ISIN LT0000411167), effective as of the time of this announcement. New subscription orders are no longer accepted. As of the time of this announcement, Nasdaq Exchange Members shall not accept any new subscription orders from investors. By 12:00 midday today (5 June 2025) the Members may only enter into the Exchange Trading System previously received buy orders that have not yet been entered. Any orders entered into the Exchange Trading System after 12:00 will not be processed and will not be eligible for bond allocation. Please note that the results...

                                                                Press Release Atos to deliver key IT services and applications for UEFA Nations League Finals™ 2025 Paris, France – 5 June, 2025 – Atos, the Official Information Technology Partner of UEFA National Team Football, will deliver key IT services and applications support for the UEFA Nations League Finals™(UNLF) 2025, taking place from June 4 to June 8, 2025, in Germany. Atos’ expertise will once again support hundreds of millions of fans worldwide to share the electrifying experience of one of the highest profile football tournaments. To provide the best experience for all stakeholders, from the European football family to fans and media, Atos will be responsible for managing core IT planning and operations systems all requiring the highest level of reliability,...

HYDERABAD, INDIA & REYKJAVIK, ICELAND (June 5, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars, thereby, speeding up...

HYDERABAD, India and REYKJAVIK, Iceland, June 05, 2025 (GLOBE NEWSWIRE) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide (“Alvotech”), and Dr. Reddy’s Laboratories Ltd., (BSE: 500124 | NSE: DRREDDY | NYSE: RDY | NSEIFSC: DRREDDY, along with its subsidiaries hereafter referred to as “Dr. Reddy’s”), today announced that the companies have entered into a collaboration and license agreement to co-develop, manufacture and commercialize a biosimilar candidate to Keytruda® (pembrolizumab) for global markets. Keytruda® (pembrolizumab) is indicated for the treatment of numerous cancer types. In 2024, worldwide sales of Keytruda were US$29.5 billion [1]. The collaboration combines Dr. Reddy’s and Alvotech’s proven capabilities in biosimilars,...